|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SOCS5 |
Gene summary for SOCS5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SOCS5 | Gene ID | 9655 |
| Gene name | suppressor of cytokine signaling 5 | |
| Gene Alias | CIS6 | |
| Cytomap | 2p21 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | O75159 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9655 | SOCS5 | male-WTA | Human | Thyroid | PTC | 8.10e-12 | 2.31e-02 | 0.1037 |
| 9655 | SOCS5 | PTC01 | Human | Thyroid | PTC | 9.00e-04 | -6.65e-04 | 0.1899 |
| 9655 | SOCS5 | PTC04 | Human | Thyroid | PTC | 1.09e-08 | 6.86e-02 | 0.1927 |
| 9655 | SOCS5 | PTC05 | Human | Thyroid | PTC | 2.21e-07 | 1.70e-01 | 0.2065 |
| 9655 | SOCS5 | PTC06 | Human | Thyroid | PTC | 3.89e-13 | 1.02e-01 | 0.2057 |
| 9655 | SOCS5 | PTC07 | Human | Thyroid | PTC | 1.33e-15 | 1.41e-01 | 0.2044 |
| 9655 | SOCS5 | ATC12 | Human | Thyroid | ATC | 3.23e-18 | 3.26e-01 | 0.34 |
| 9655 | SOCS5 | ATC13 | Human | Thyroid | ATC | 3.99e-24 | 5.94e-01 | 0.34 |
| 9655 | SOCS5 | ATC2 | Human | Thyroid | ATC | 5.71e-07 | 4.76e-01 | 0.34 |
| 9655 | SOCS5 | ATC4 | Human | Thyroid | ATC | 1.26e-17 | 4.27e-01 | 0.34 |
| 9655 | SOCS5 | ATC5 | Human | Thyroid | ATC | 4.26e-37 | 6.49e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004232634 | Thyroid | ATC | negative regulation of phosphorylation | 203/6293 | 385/18723 | 5.30e-15 | 3.53e-13 | 203 |
| GO:005134834 | Thyroid | ATC | negative regulation of transferase activity | 144/6293 | 268/18723 | 7.63e-12 | 2.91e-10 | 144 |
| GO:000646925 | Thyroid | ATC | negative regulation of protein kinase activity | 114/6293 | 212/18723 | 1.06e-09 | 2.69e-08 | 114 |
| GO:003367325 | Thyroid | ATC | negative regulation of kinase activity | 122/6293 | 237/18723 | 9.19e-09 | 1.94e-07 | 122 |
| GO:0038127111 | Thyroid | ATC | ERBB signaling pathway | 71/6293 | 121/18723 | 1.31e-08 | 2.69e-07 | 71 |
| GO:0007173111 | Thyroid | ATC | epidermal growth factor receptor signaling pathway | 63/6293 | 108/18723 | 1.15e-07 | 1.92e-06 | 63 |
| GO:0045785210 | Thyroid | ATC | positive regulation of cell adhesion | 194/6293 | 437/18723 | 1.40e-06 | 1.75e-05 | 194 |
| GO:004205916 | Thyroid | ATC | negative regulation of epidermal growth factor receptor signaling pathway | 21/6293 | 28/18723 | 8.94e-06 | 8.95e-05 | 21 |
| GO:190118515 | Thyroid | ATC | negative regulation of ERBB signaling pathway | 23/6293 | 32/18723 | 1.09e-05 | 1.07e-04 | 23 |
| GO:190118415 | Thyroid | ATC | regulation of ERBB signaling pathway | 45/6293 | 79/18723 | 1.68e-05 | 1.55e-04 | 45 |
| GO:004205814 | Thyroid | ATC | regulation of epidermal growth factor receptor signaling pathway | 42/6293 | 73/18723 | 2.29e-05 | 2.02e-04 | 42 |
| GO:003440512 | Thyroid | ATC | response to fluid shear stress | 24/6293 | 35/18723 | 2.49e-05 | 2.16e-04 | 24 |
| GO:006109913 | Thyroid | ATC | negative regulation of protein tyrosine kinase activity | 20/6293 | 31/18723 | 4.20e-04 | 2.51e-03 | 20 |
| GO:000717613 | Thyroid | ATC | regulation of epidermal growth factor-activated receptor activity | 19/6293 | 30/18723 | 8.20e-04 | 4.52e-03 | 19 |
| GO:005073211 | Thyroid | ATC | negative regulation of peptidyl-tyrosine phosphorylation | 32/6293 | 59/18723 | 8.74e-04 | 4.72e-03 | 32 |
| GO:006109712 | Thyroid | ATC | regulation of protein tyrosine kinase activity | 45/6293 | 90/18723 | 9.39e-04 | 5.04e-03 | 45 |
| GO:001821211 | Thyroid | ATC | peptidyl-tyrosine modification | 156/6293 | 378/18723 | 1.01e-03 | 5.36e-03 | 156 |
| GO:000716225 | Thyroid | ATC | negative regulation of cell adhesion | 127/6293 | 303/18723 | 1.45e-03 | 7.47e-03 | 127 |
| GO:00181086 | Thyroid | ATC | peptidyl-tyrosine phosphorylation | 153/6293 | 375/18723 | 1.96e-03 | 9.48e-03 | 153 |
| GO:007149811 | Thyroid | ATC | cellular response to fluid shear stress | 14/6293 | 21/18723 | 1.99e-03 | 9.54e-03 | 14 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SOCS5 | SNV | Missense_Mutation | c.224N>A | p.Ser75Tyr | p.S75Y | O75159 | protein_coding | tolerated_low_confidence(0.1) | benign(0.009) | TCGA-B6-A0WX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| SOCS5 | SNV | Missense_Mutation | rs757917355 | c.573N>C | p.Met191Ile | p.M191I | O75159 | protein_coding | tolerated(1) | benign(0) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SOCS5 | SNV | Missense_Mutation | rs776060821 | c.529C>G | p.Leu177Val | p.L177V | O75159 | protein_coding | tolerated(0.06) | possibly_damaging(0.493) | TCGA-VS-A9UV-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | PD |
| SOCS5 | SNV | Missense_Mutation | c.1059N>T | p.Arg353Ser | p.R353S | O75159 | protein_coding | tolerated(0.76) | benign(0.003) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SOCS5 | SNV | Missense_Mutation | c.463N>T | p.Arg155Cys | p.R155C | O75159 | protein_coding | tolerated(0.06) | probably_damaging(0.996) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| SOCS5 | SNV | Missense_Mutation | rs373780921 | c.472G>A | p.Val158Ile | p.V158I | O75159 | protein_coding | tolerated(0.29) | benign(0.003) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| SOCS5 | SNV | Missense_Mutation | c.408N>T | p.Leu136Phe | p.L136F | O75159 | protein_coding | tolerated(0.26) | benign(0.005) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SOCS5 | SNV | Missense_Mutation | novel | c.1576N>T | p.Arg526Cys | p.R526C | O75159 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SOCS5 | SNV | Missense_Mutation | c.961N>G | p.Asn321Asp | p.N321D | O75159 | protein_coding | tolerated(1) | benign(0) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SOCS5 | SNV | Missense_Mutation | c.131A>G | p.Asn44Ser | p.N44S | O75159 | protein_coding | tolerated_low_confidence(0.99) | benign(0) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |